Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
AtriCure
ATRC
AtriCure
Global Cardiac Ablation Market Will Face Intensified Challenges Yet Rebound
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
07 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$40.00
5.4% undervalued
intrinsic discount
16 Aug
US$37.84
Loading
1Y
44.7%
7D
6.2%
Author's Valuation
US$40.0
5.4% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$40.0
5.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-57m
700m
2014
2017
2020
2023
2025
2026
2028
Revenue US$699.6m
Earnings US$86.9m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
11.42%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.56%
Calculation
US$86.90m
Earnings '28
x
29.80x
PE Ratio '28
=
US$2.59b
Market Cap '28
US$2.59b
Market Cap '28
/
52.84m
No. shares '28
=
US$49.00
Share Price '28
US$49.00
Share Price '28
Discounted to 2025 @ 7.57% p.a.
=
US$39.36
Fair Value '25
